-
Views
-
Cite
Cite
Anders Eriksson, Morteza Shafazand, Eva Jennische, Ivar Lönnroth, Stefan Lange, Antisecretory Factor-induced Regression of Crohn's Disease in a Weak Responder to Conventional Pharmacological Treatment, Inflammatory Bowel Diseases, Volume 9, Issue 6, 1 November 2003, Pages 398–400, https://doi.org/10.1097/00054725-200311000-00013
Close - Share Icon Share
Extract
To the Editor:
A 38-year-old man with a 20-year history of Crohn's disease, who had previously undergone 2 sessions of colonic surgery (in 1985 and 1986) with removal of the transverse and descending part of colon with a remaining total colon length of about 50 cm. Those episodes were followed by an ileocecal resection (in 1988) with removal of about 10 cm of terminal ileum. He was admitted to our hospital in February 2001 due to a severe deterioration of his condition. Over the previous several years, he had been treated with corticosteroids, sulfalazine/5-ASA, metronidazole, immunosuppression, and imfliximab. During 2000, the patient had suffered from progressive abdominal pain, weight loss (25% of his normal weight), and bloody stools (>15/day). Laboratory tests confirmed increased activity of Crohn's disease with B-hemoglobin 93g/L (132–166), B-leukocyte counts 12,6 ×109 (4–10), B-platelets 395 ×109 (150–300), B-sedimentation rate 19 mm/hour (<13), S-C-reactive protein 64 mg/L (<5), S-albumin 27 g/L (40–51), S-haptoglobin 2.9 g/L (0.35–1.9) and S-orosomucoid 1.3 g/L (0.54–1.2). Colonoscopy revealed a discolored, dehaustrated, devitalized mucosa of the entire remaining large intestine and about 10 cm of terminal neo-ileum. No spontaneous bleeding was found, but after contact with the endoscope, small bleeding spots in the mucosa were noted in the region of ileo-colonic anastomosis. Small bowel radiography demonstrated a slight luminal reduction in the terminal part of neo-ileum. No scintigraphy examination was done at this moment. On the ward, the patient received total parenteral nutrition and high doses of intravenous betamethasone (4 mg twice daily in 14 days) with no clinical or laborative improvements.
